COMPASS Pathways PLC (CMPS): Price to Sales

The price-to-sales ratio dynamics for COMPASS Pathways plc (CMPS) demonstrate volatility driven by strict regulatory oversight and costly FDA cycles. The value reflects the most recent metric reading. Business stability relies on exclusive COMP360 patents for the treatment of depression. Growth prospects are determined by intensive clinical trials and the anticipation of scientific and technological breakthroughs in the field of psychedelic medicine.

CMPS Compass Pathways: Price-to-Revenue Ratio in the range 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Compass Pathways (CMPS)

- share price and consensus valuation forecast:

Price Performance Chart compasspathways.com|CMPS - Price Target Chart

- stock exchange capitalization data:

Market Value Compass Pathways|CMPS - Enterprise Value

- shareholders' equity book value data:

Accounting Value per Share COMPASS Pathways|CMPS - Company Book Value|Market-to-Book Ratio compasspathways.com|CMPS - Aggregate Company Assets

- debt obligations and liquidity statistics:

- business earnings and investment ratios data:

CMPS - Net Income|Expected Net Income COMPASS Pathways plc|CMPS - Price to Earnings Ratio|Price to Expected Earnings Ratio COMPASS Pathways PLC|CMPS - PEG Multiple|EV/EBITDA Multiple Compass Pathways|CMPS - Operating profit before deduction of amortization|Earnings per share for the last four quarters COMPASS Pathways|CMPS - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months compasspathways.com|CMPS - Net earnings per share growth this year|Expected earnings per share growth for next year COMPASS Pathways plc

- total revenue and sales volume data:

CMPS - Revenue and Sales Volume|Projected Sales Volume compasspathways.com|CMPS - Market Cap to Revenue|Market Cap to Future Revenue Ratio Compass Pathways

General company analysis:CMPS compasspathways.com

Original product of COMPASS Pathways PLC

Investors are seeking fundamental benchmarks in the COMPASS Pathways plc (CMPS) financial reports to assess the business value relative to its actual revenues. By analyzing the price-to-sales multiple, one can understand how the market values the biotech sector's ability to monetize developments while accounting for high ESG compliance costs and ethical chemical disposal, balancing the risk of overpayment against the cost of missed opportunities.

Competitors of COMPASS Pathways plc

ALKS (alkermes.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Avadel Pharmaceuticals plc AVDL|atai Life Sciences NV (ATAI) - Price to Sales|GH Research Corp - P/S Multiple|Mind Medicine Corp (MNMD) - Market Cap to Revenue|LB Pharmaceuticals Inc (LBRX) - Price-to-Revenue Ratio|Price to Sales brightmindsbio.com (DRUG)|Price-to-Revenue Ratio Vanda Pharmaceuticals Inc.|Market Cap to Revenue Cybin Corp (CYBN)|Price-to-Revenue Ratio Alto Neuro (ANRO)|NRXP: Price-to-Sales Ratio|P/S Multiple CING (Cingulate)|P/S Multiple Silo Pharma Inc. SILO|CPHI - Price-to-Revenue Ratio|Price-to-Revenue Coefficient clearmindmedicine.com CMND|Psyence Biomedical Limited (PBM) - Price-to-Revenue Ratio|SPRC - Price-to-Revenue Coefficient|Market Cap to Revenue SEEL|VRPX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Karuna Therapeutics, Inc. (KRTX)